Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IPXL's Cash to Debt is ranked higher than
95% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. IPXL: No Debt )
IPXL' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: No Debt

Equity to Asset 0.84
IPXL's Equity to Asset is ranked higher than
88% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. IPXL: 0.84 )
IPXL' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.84
Current: 0.84

0.2
0.84
F-Score: 5
Z-Score: 8.42
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1.25
IPXL's Operating margin (%) is ranked higher than
55% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. IPXL: -1.25 )
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74   Max: 44.72
Current: -1.25

-1418.74
44.72
Net-margin (%) 19.80
IPXL's Net-margin (%) is ranked higher than
92% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. IPXL: 19.80 )
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35   Max: 46
Current: 19.8

-1376.35
46
ROE (%) 12.50
IPXL's ROE (%) is ranked higher than
86% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. IPXL: 12.50 )
IPXL' s 10-Year ROE (%) Range
Min: -426.49   Max: 93.86
Current: 12.5

-426.49
93.86
ROA (%) 10.16
IPXL's ROA (%) is ranked higher than
92% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.09 vs. IPXL: 10.16 )
IPXL' s 10-Year ROA (%) Range
Min: -153.23   Max: 36.12
Current: 10.16

-153.23
36.12
ROC (Joel Greenblatt) (%) -2.27
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.47 vs. IPXL: -2.27 )
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.43   Max: 258.5
Current: -2.27

-231.43
258.5
Revenue Growth (%) -17.80
IPXL's Revenue Growth (%) is ranked higher than
50% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. IPXL: -17.80 )
IPXL' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 203.4
Current: -17.8

0
203.4
EBITDA Growth (%) -24.50
IPXL's EBITDA Growth (%) is ranked higher than
53% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. IPXL: -24.50 )
IPXL' s 10-Year EBITDA Growth (%) Range
Min: -34.9   Max: 61.6
Current: -24.5

-34.9
61.6
EPS Growth (%) -27.30
IPXL's EPS Growth (%) is ranked higher than
56% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPXL: -27.30 )
IPXL' s 10-Year EPS Growth (%) Range
Min: -32.2   Max: 55.1
Current: -27.3

-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

IPXL Guru Trades in Q3 2013

Steven Cohen 177,555 sh (+37.43%)
Jim Simons 1,065,200 sh (+12.56%)
RS Investment Management 2,534,898 sh (+2.01%)
» More
Q4 2013

IPXL Guru Trades in Q4 2013

Paul Tudor Jones 11,100 sh (New)
Jim Simons 1,408,300 sh (+32.21%)
RS Investment Management 2,350,484 sh (-7.28%)
Steven Cohen 17,474 sh (-90.16%)
» More
Q1 2014

IPXL Guru Trades in Q1 2014

John Hussman 220,000 sh (New)
Steven Cohen 63,998 sh (+266.25%)
Paul Tudor Jones 18,000 sh (+62.16%)
Jim Simons 1,046,000 sh (-25.73%)
RS Investment Management 1,328,437 sh (-43.48%)
» More
Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Add 40.91%0.21%$23.6 - $30.68 $ 24.43-9%310000
John Hussman 2014-03-31 New Buy0.44%$22.02 - $27.91 $ 24.43-2%220000
John Hussman 2012-03-31 Sold Out 0.11%$18.64 - $24.37 $ 24.4318%0
Joel Greenblatt 2012-03-31 Sold Out 0.05%$18.64 - $24.37 $ 24.4318%0
Joel Greenblatt 2011-12-31 Reduce -88.51%0.47%$16.53 - $20.75 $ 24.4331%21057
Joel Greenblatt 2011-09-30 Reduce -40.22%0.38%$15.26 - $21.56 $ 24.4325%183187
Joel Greenblatt 2011-06-30 Add 446.09%0.76%$20.21 - $28.73 $ 24.43-3%306452
George Soros 2011-06-30 Sold Out $20.21 - $28.73 $ 24.43-3%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 904.80
IPXL's P/E(ttm) is ranked higher than
65% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.60 vs. IPXL: 904.80 )
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 1136.3
Current: 904.8

4.04
1136.3
P/B 2.07
IPXL's P/B is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. IPXL: 2.07 )
IPXL' s 10-Year P/B Range
Min: 1.32   Max: 18.07
Current: 2.07

1.32
18.07
P/S 3.15
IPXL's P/S is ranked higher than
59% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.45 vs. IPXL: 3.15 )
IPXL' s 10-Year P/S Range
Min: 1.17   Max: 19.49
Current: 3.15

1.17
19.49
PFCF 59.59
IPXL's PFCF is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 59.59 )
IPXL' s 10-Year PFCF Range
Min: 2.31   Max: 74.83
Current: 59.59

2.31
74.83
EV-to-EBIT -543.98
IPXL's EV-to-EBIT is ranked higher than
77% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. IPXL: -543.98 )
IPXL' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 628.6
Current: -543.98

1.8
628.6
PEG 198.61
IPXL's PEG is ranked higher than
80% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 198.61 )
IPXL' s 10-Year PEG Range
Min: 0.14   Max: 195.7
Current: 198.61

0.14
195.7
Shiller P/E 15.86
IPXL's Shiller P/E is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 15.86 )
IPXL' s 10-Year Shiller P/E Range
Min: 10.23   Max: 61.99
Current: 15.86

10.23
61.99
Current Ratio 5.27
IPXL's Current Ratio is ranked higher than
84% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. IPXL: 5.27 )
IPXL' s 10-Year Current Ratio Range
Min: 1.12   Max: 10.65
Current: 5.27

1.12
10.65
Quick Ratio 4.65
IPXL's Quick Ratio is ranked higher than
84% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. IPXL: 4.65 )
IPXL' s 10-Year Quick Ratio Range
Min: 0.63   Max: 10.07
Current: 4.65

0.63
10.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.33
IPXL's Price/Net Cash is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 7.33 )
IPXL' s 10-Year Price/Net Cash Range
Min: 5.39   Max: 436.33
Current: 7.33

5.39
436.33
Price/Net Current Asset Value 4.74
IPXL's Price/Net Current Asset Value is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 4.74 )
IPXL' s 10-Year Price/Net Current Asset Value Range
Min: 3.09   Max: 368.75
Current: 4.74

3.09
368.75
Price/Tangible Book 2.21
IPXL's Price/Tangible Book is ranked higher than
79% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. IPXL: 2.21 )
IPXL' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 26.35
Current: 2.21

1.45
26.35
Price/DCF (Projected) 1.50
IPXL's Price/DCF (Projected) is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.80 vs. IPXL: 1.50 )
IPXL' s 10-Year Price/DCF (Projected) Range
Min: 0.96   Max: 4.39
Current: 1.5

0.96
4.39
Price/Median PS Value 1.06
IPXL's Price/Median PS Value is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. IPXL: 1.06 )
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 25.85
Current: 1.06

0.41
25.85
Price/Peter Lynch Fair Value 143.70
IPXL's Price/Peter Lynch Fair Value is ranked lower than
65% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 143.70 )
IPXL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.18   Max: 155.41
Current: 143.7

0.18
155.41
Price/Graham Number 8.66
IPXL's Price/Graham Number is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. IPXL: 8.66 )
IPXL' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 31.77
Current: 8.66

0.68
31.77
Earnings Yield (Greenblatt) 3.40
IPXL's Earnings Yield (Greenblatt) is ranked higher than
62% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. IPXL: 3.40 )
IPXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 55.9
Current: 3.4

0.2
55.9
Forward Rate of Return (Yacktman) 7.80
IPXL's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. IPXL: 7.80 )
IPXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.9   Max: 6.1
Current: 7.8

-12.9
6.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany
Impax Laboratories, Inc., a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. Bioequivalent pharmaceuticals, commonly referred to as 'generics,' are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under its established nonproprietary drug names rather than by a brand name. Bioequivalent pharmaceuticals contain the same active ingredient and are of the same route of administration, dosage form, strength and indication(s) as brand-name pharmaceuticals already approved for use in the United States by the Food and Drug Administration ('FDA'). In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas and having technically challenging drug-delivery mechanisms or limited competition. In the brand-name pharmaceuticals market it develops products for the treatment of central nervous system disorders. The Company has two reportable segments namely 'Global Pharmaceuticals Division', ('Global Division') and the 'Impax Pharmaceuticals Division', ('Impax Division'). The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The active chemical raw materials, essential to its business, are generally readi
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Other Websites
Attention Impax Laboratories, Inc. Investors: Impax Misled Investors According to a Recently Filed... Aug 19 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Aug 18 2014
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Impax... Aug 15 2014
IMPAX LABORATORIES INC Financials Aug 15 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Impax... Aug 15 2014
Pomerantz Law Firm Announces the Filing of a Class Action Against Impax Laboratories, Inc. and... Aug 13 2014
SHAREHOLDER ALERT: Investigation on Behalf of Impax Laboratories, Inc. Investors Announced by Law... Aug 11 2014
Lifshitz & Miller Law Firm Announces Investigation of Cobalt International Energy, Inc., DreamWorks... Aug 08 2014
Impax Laboratories Inc Stock Upgraded (IPXL) Aug 08 2014
Impax's Second Quarter 2014 Revenues Increased 45% to $188.1 Million Aug 06 2014
IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2014
Impax's Second Quarter 2014 Revenues Increased 45% to $188.1 Million Aug 06 2014
Q2 2014 Impax Laboratories Earnings Release - Before Market Open Aug 06 2014
FDA Performs Inspection of Impax's Hayward Facility Aug 04 2014
IMPAX LABORATORIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 04 2014
FDA Performs Inspection of Impax's Hayward Facility Aug 04 2014
Impax Shares Plunge Post FDA Inspection of Taiwan Facility Jul 31 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Jul 30 2014
INVESTOR ALERT: Investigation of Impax Laboratories, Inc. Announced by Glancy Binkow & Goldberg LLP Jul 29 2014
Impax Labs shares slump after FDA inspection Jul 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide